Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Eli Lilly and Co. (LLY) emerged as a beacon of optimism last week in a market filled with uncertainty and volatility. Shares soared over 14% ...

Coya Therapeutics, Inc.’s COYA share price has surged by 6.94%, which has investors questioning if this is right time to sell ...

Lilly plans to submit orforglipron for approval in weight management by the end of 2025, with a T2D application to follow in ...

Ozempic, originally prescribed for type 2 diabetes, is now widely used off-label for weight loss, but rapid results can lead ...

The latest pharmacological treatment approved by the FDA for type 2 diabetes combines glucagon-like peptide-1 (GLP-1 ... MOUNJARO (tirzepatide) injection, for subcutaneous use. U.S. Food & Drug ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs. By Gina Kolata and Rebecca Robbins A daily pill may be as ...

Tucson, Arizona – A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists ...

Boettcher II Chair in Atherosclerosis at the University of Colorado Anschutz Medical Campus, said orforglipron could have a role as an alternative to subcutaneous GLP-1s based on the topline results.